By Julie Poteet, OD, MS, CNS, FOWNS
As optometrists, we are increasingly called upon to think beyond the confines of the eye. The retina, after all, is the only visible extension of the brain—and cognitive decline often casts its earliest shadows in our exam rooms. Subtle changes in contrast sensitivity, visual field loss, or retinal microvasculature may precede formal diagnoses of neurodegenerative disease. It’s in this spirit of integrative, systems-based care that I want to share the profound implications of a recent clinical trial led by Dean Ornish, MD, that deserves our attention—not just as clinicians, but as caregivers, daughters, mothers, and women deeply invested in brain health.
A FIRST-OF-ITS-KIND STUDY
Published in Alzheimer’s Research & Therapy in June 2024, this randomized controlled trial—the first of its kind—demonstrated that a comprehensive lifestyle medicine approach can improve or stabilize cognitive function in people with early Alzheimer’s disease or mild cognitive impairment (MCI) in just 20 weeks. Yes, you read that correctly: not slow, not delay—improve.
The study enrolled 51 adults, aged 45 to 90, diagnosed with MCI or early-stage Alzheimer’s. Participants were randomized into either a multimodal lifestyle intervention group or a control group that continued usual care. Those in the intervention arm engaged in a rigorously supported regimen of:
• A whole-food, plant-based diet low in saturated fat and refined carbohydrates
• Moderate daily exercise and resistance training
• Daily stress management techniques such as breathing, stretching, and meditation
• Weekly support sessions involving caregivers or spouses
It’s worth emphasizing that this was not a pharmaceutical trial. No new drugs were administered. What changed—radically—was the terrain of the participants’ daily lives.
WHAT DID THEY FIND?
After just 20 weeks:
• 71% of those in the lifestyle group showed measurable improvement or stabilization in cognitive and functional testing.
• In contrast, none of the control group participants improved. Over two-thirds of them declined.
• Biomarkers of Alzheimer’s pathology, including the Aβ₄₂/₄₀ ratio, improved significantly in the intervention group and worsened in the control group.
• Markers of metabolic health (HbA1c, insulin), inflammation (GlycA), and biological aging (telomere length) also shifted in favorable directions.
• A dose-response effect was seen—greater adherence to the lifestyle changes correlated with greater cognitive improvement.
Let that sink in: the degree to which people changed how they ate, moved, relaxed, and connected directly mirrored how much their cognition improved.
WHAT DOES THIS MEAN FOR EYE CARE?
In optometry, we routinely assess neural tissue. The ganglion cells of the retina, the optic nerve, and visual pathways—all vulnerable to the same inflammatory and metabolic forces implicated in Alzheimer’s—give us a powerful vantage point into early neurodegeneration.
If lifestyle medicine can halt or even reverse cognitive decline, it is not a stretch to suggest it may also influence the trajectory of vision-threatening diseases like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy. Many of these conditions share common root mechanisms: oxidative stress, chronic inflammation, vascular dysfunction, and impaired mitochondrial health. Because of this, many call macular degeneration Alzheimer’s of the eye.
We’ve seen, for instance, studies suggesting that Mediterranean-style diets are protective against AMD progression. We’ve watched the DREAM study challenge assumptions about omega-3s and dry eye, while other trials spotlight gut microbiome diversity as a key modulator of ocular inflammation. The Ornish study adds yet another thread: that a systems-based lifestyle approach may have a role not only in prevention, but in reversal.
A WAKE-UP CALL FOR WOMEN
As women, we carry a disproportionate burden of Alzheimer’s disease—two-thirds of all cases affect women. Hormonal transitions, caregiving stress, nutritional deficiencies, and longer lifespans all contribute to our heightened risk. But risk is not destiny.
This study gives us something rarely offered in discussions of neurodegeneration: hope. It also gives us a roadmap.
And while implementing every element of the Ornish protocol may feel daunting for the average patient, optometrists are well-positioned to lead with small steps. We already counsel patients on diet, supplements, and cardiovascular risk. Why not begin to connect those dots to retinal and cognitive health?
HOW WE CAN COUNSEL PATIENTS
Here are three practical ways to bring this into your exam room:
1. Screen for Cognitive Risk in the History
Ask about memory changes, mental fog, or family history of dementia. Patients often open up when we ask gently. Consider MoCA or digital cognitive screeners if you’re comfortable.
2. Educate on Brain-Eye Diets
Highlight the synergy between retinal and cognitive nutrition:
– Encourage leafy greens, colorful vegetables, berries and fatty fish.
– Recommend limiting refined sugars, processed foods, and red meats.
– For willing patients, suggest adding a plant-based meal each day.
3. Promote Mind–Body Wellness
Stress, poor sleep, and social isolation accelerate neuroinflammation. Ask: “How do you relax?” Offer resources like meditation apps or referrals to yoga and walking groups. Normalize lifestyle as medicine.
FINAL THOUGHTS
The Ornish study offers a paradigm shift: that Alzheimer’s disease is not always a one-way street. As eye doctors, we can become agents of change—teaching that vision care is brain care, and that every meal, breath, and moment of movement matters.
Let’s embrace our unique role at the intersection of neurology, vision, and lifestyle—and start writing a new chapter of care. Not only for our patients, but for ourselves.
